Clinical Trials
5
Active:0
Completed:2
Trial Phases
2 Phases
Phase 3:2
Phase 4:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 4
3 (60.0%)Phase 3
2 (40.0%)Optimizing Infarct Size by Transforming Emergent Stenting Into an Elective Procedure Study
Phase 4
- Conditions
- Myocardial Infarction
- First Posted Date
- 2011-10-31
- Last Posted Date
- 2011-10-31
- Lead Sponsor
- Marco Valgimigli
- Target Recruit Count
- 100
- Registration Number
- NCT01462188
- Locations
- 🇮🇹
U.O. Cardiologia, Ferrara, Emilia Romagna, Italy
Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study
Phase 3
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Marco Valgimigli
- Target Recruit Count
- 1606
- Registration Number
- NCT01385319
- Locations
- 🇭🇺
Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary
🇮🇹Ospedale San Donato, Arezzo, AR, Italy
🇮🇹Ospedali Riuniti di Bergamo, Bergamo, BG, Italy
Synergy Between Stent and Drugs to Avoid Ischemic Recurrences After Percutaneous Coronary Intervention
Phase 4
Completed
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Marco Valgimigli
- Target Recruit Count
- 1700
- Registration Number
- NCT00611286
- Locations
- 🇮🇹
Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Emilia Romagna, Italy
Predictive Value of Allen's Test Result in Elective Patients Undergoing Coronary Catheterization Through Radial Approach
Phase 3
Completed
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2008-01-18
- Last Posted Date
- 2011-10-27
- Lead Sponsor
- Marco Valgimigli
- Target Recruit Count
- 203
- Registration Number
- NCT00597324
- Locations
- 🇮🇹
University Hospital, Ferrara, FE, Italy
Multicentre 2x2 Factorial Randomised Study Comparing Tirofiban Versus Abciximab and SES Versus BMS in AMI
Phase 4
- Conditions
- Myocardial Infarction
- First Posted Date
- 2005-09-29
- Last Posted Date
- 2011-10-27
- Lead Sponsor
- Marco Valgimigli
- Target Recruit Count
- 744
- Registration Number
- NCT00229515
- Locations
- 🇮🇹
Cattedra di Cardiologia, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy
News
No news found